HGA’s CEO, Joel White, spoke with Fierce Healthcare about the impact a divided Congress could have on health policy in 2023.
Republicans could use their oversight tools to scrutinize the implementation of the Inflation Reduction Act that gave Medicare the power to negotiate for lower drug prices for a small subset of Medicare Part B drugs, said Joel White, CEO of consulting firm Horizon Government Affairs and a former hill staffer.
“This is a sea change in how drug pricing works in America,” White said in an interview with Fierce Healthcare. “The law basically says for four years you get to do this without issuing formal regulations.”